Viridian Therapeutics (NASDAQ:VRDN) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Viridian Therapeutics from “strong sell” to “sell”, but analyst sentiment remains broadly positive overall.
• Across recent coverage, 12 analysts rate the stock a Buy, with only one Hold and one Sell; the consensus rating is Moderate Buy and the average price target is about $37.31.
• Viridian shares were down 2.3% to $16.61, while the company also reported a smaller-than-expected quarterly loss and topped revenue estimates, even as it completed a $350 million financing that could dilute shareholders.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

A number of other research analysts also recently issued reports on the company. HC Wainwright cut their price target on Viridian Therapeutics from $34.00 to $22.00 and set a "buy" rating on the stock in a report on Tuesday, March 31st. The Goldman Sachs Group cut their price target on Viridian Therapeutics from $36.00 to $31.00 and set a "buy" rating on the stock in a report on Tuesday, April 7th. Royal Bank Of Canada lifted their price target on Viridian Therapeutics from $30.00 to $34.00 and gave the company an "outperform" rating in a report on Wednesday. Truist Financial cut their price target on Viridian Therapeutics from $36.00 to $33.00 and set a "buy" rating on the stock in a report on Tuesday, April 21st. Finally, Evercore reiterated an "outperform" rating and issued a $44.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $37.31.

Viridian Therapeutics Trading Down 2.3%

Shares of NASDAQ:VRDN opened at $16.61 on Friday. Viridian Therapeutics has a 12-month low of $12.07 and a 12-month high of $34.29. The business's fifty day simple moving average is $21.57 and its 200-day simple moving average is $26.94. The company has a market capitalization of $1.71 billion, a PE ratio of -5.00 and a beta of 0.82. The company has a current ratio of 15.15, a quick ratio of 12.65 and a debt-to-equity ratio of 0.10.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.04 million. During the same period last year, the business posted ($0.87) EPS. The business's revenue was up 95.8% compared to the same quarter last year. As a group, equities research analysts predict that Viridian Therapeutics will post -3.62 earnings per share for the current fiscal year.

Institutional Trading of Viridian Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hudson Bay Capital Management LP lifted its position in Viridian Therapeutics by 46.6% during the 3rd quarter. Hudson Bay Capital Management LP now owns 175,251 shares of the company's stock worth $3,782,000 after acquiring an additional 55,689 shares during the period. Fisher Asset Management LLC lifted its holdings in shares of Viridian Therapeutics by 135.6% in the 3rd quarter. Fisher Asset Management LLC now owns 1,201,226 shares of the company's stock valued at $25,922,000 after buying an additional 691,267 shares during the period. Propel Bio Management LLC acquired a new position in shares of Viridian Therapeutics in the 3rd quarter valued at about $1,942,000. Y Intercept Hong Kong Ltd lifted its holdings in shares of Viridian Therapeutics by 430.3% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company's stock valued at $1,394,000 after buying an additional 52,414 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Viridian Therapeutics by 411.8% in the 3rd quarter. SG Americas Securities LLC now owns 62,118 shares of the company's stock valued at $1,341,000 after buying an additional 49,981 shares during the period.

More Viridian Therapeutics News

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates across several future periods, including FY2026, FY2027, FY2028, FY2029 and FY2030, while keeping a Buy rating and a $22 price target, suggesting improving longer-term outlook for Viridian Therapeutics.
• Positive Sentiment: Needham & Company reiterated its Buy rating on Viridian Therapeutics, adding to the recent cluster of bullish analyst support. Viridian Therapeutics' (VRDN) "Buy" Rating Reiterated at Needham & Company LLC
• Neutral Sentiment: Multiple brokerage updates lifted target prices on VRDN, with one report citing an average target of about $37.07, reflecting continued optimism from analysts. Brokerages Set Viridian Therapeutics, Inc. NASDAQ: VRDN Target Price at $37.07
• Negative Sentiment: Viridian Therapeutics completed pricing on an upsized concurrent offering of 1.75% convertible senior notes due 2032 and common stock for $350 million, which can dilute existing shareholders and usually weighs on the stock near term. Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings...
• Negative Sentiment: Market articles also highlighted the financing as a key reason for recent volatility, even as investors look ahead to commercialization of its drug pipeline. Viridian (VRDN) Climbs 33% on Looming Drug Commercialization

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.